{"id":8928,"date":"2024-04-30T02:16:35","date_gmt":"2024-04-30T02:16:35","guid":{"rendered":"https:\/\/economicherald.net\/?p=8928"},"modified":"2024-04-30T02:16:35","modified_gmt":"2024-04-30T02:16:35","slug":"asx-health-stocks-clarity-pharma-says-its-prostate-cancer-treatment-has-achieved-complete-response","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=8928","title":{"rendered":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019"},"content":{"rendered":"

Clarity Pharma doses first patient with two cycles of 67Cu-SAR-bisPSMA at 8GBq\u00a0
\nThe patient achieved a complete response to treatment
\nThis was part of Clarity\u2019s theranostic SECuRE trial<\/p>\n

\u00a0<\/p>\n

Clarity Pharma (ASX:CU6)<\/a> <\/strong>jumped +7% this morning after revealing that the first patient to be dosed with two cycles of 67Cu-SAR-bisPSMA<\/strong> at 8GBq<\/strong> achieved a complete response to treatment based on RECIST criteria<\/em>.<\/p>\n

The patient received the first cycle of 67Cu-SAR-bisPSMA as part of Cohort 2 of Clarity\u2019s theranostic SECuRE trial<\/strong>, which is evaluating the drug in patients with mCRPC (metastatic castration-resistant prostate cancer).<\/p>\n

Prior to receiving this drug, the patient had failed multiple lines of treatment, including hormone therapy, an investigational agent and chemotherapy.<\/p>\n

Following the administration of the first cycle of 67Cu-SAR-bisPSMA, the patient showed a reduction of PSA (prostate-specific antigen) level of >99%.<\/p>\n

The patient then received a second cycle of 67Cu-SAR-bisPSMA, which resulted in further reduction of his PSA to undetectable levels.<\/p>\n

PSA is a well known marker of tumour burden and clinical response to treatment, as well as an indicator of the recurrence of prostate cancer.<\/p>\n

A complete response (absence of detectable cancer after treatment) was observed in all but one lesion, assessed by computed tomography (CT).<\/p>\n

That one lesion showed a reduction in size from 27mm to 12mm, missing the complete response cut-off by only 2mm based on RECIST (response evaluation criteria in solid tumours) assessment.<\/p>\n

Importantly, no PSMA uptake was observed in any of the lesions using 64Cu-SAR-bisPSMA following the second cycle of 67Cu-SAR-bisPSMA.<\/p>\n

Clarity\u2019s executive chairperson, Dr Alan Taylor<\/strong>, said he was very excited with this incredible response of the very first patient ever to be dosed twice at what would be considered a therapeutic dose.<\/p>\n

\u201cWe hope to replicate this remarkable result in many patients, and confirm the favourable safety profile of this agent,\u201d Taylor said.<\/p>\n

For further reading on Clarity Pharma, read here: Radiopharmaceutical emerges as the hottest space in biotech; here\u2019s what it means for Clarity Pharma<\/a><\/strong><\/em><\/p>\n

\u00a0<\/p>\n

Clarity Pharma share price today:<\/h2>\n

\u00a0<\/p>\n\n

\ufeff<\/span><\/span>\u00a0
\n<\/span><\/p>\n

The post ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Clarity Pharma doses first patient with two cycles of 67Cu-SAR-bisPSMA at 8GBq\u00a0 The patient achieved a complete response to treatment This was part of Clarity\u2019s [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":8929,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-8928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=8928\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Clarity Pharma doses first patient with two cycles of 67Cu-SAR-bisPSMA at 8GBq\u00a0 The patient achieved a complete response to treatment This was part of Clarity\u2019s [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=8928\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-30T02:16:35+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019\",\"datePublished\":\"2024-04-30T02:16:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928\"},\"wordCount\":368,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=8928\",\"name\":\"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg\",\"datePublished\":\"2024-04-30T02:16:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=8928\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8928#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=8928","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald","og_description":"Clarity Pharma doses first patient with two cycles of 67Cu-SAR-bisPSMA at 8GBq\u00a0 The patient achieved a complete response to treatment This was part of Clarity\u2019s [more...]","og_url":"https:\/\/economicherald.net\/?p=8928","og_site_name":"Economic Herald","article_published_time":"2024-04-30T02:16:35+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=8928#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=8928"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019","datePublished":"2024-04-30T02:16:35+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=8928"},"wordCount":368,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=8928#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=8928","url":"https:\/\/economicherald.net\/?p=8928","name":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019 - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=8928#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=8928#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg","datePublished":"2024-04-30T02:16:35+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=8928#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=8928"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=8928#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Clarity-Pharma-doses-first-ever-patient-with-2-cycles-of-67Cu-SAR-bisPSMA-at-8GBq-.-Picture-Getty-JOtghW.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=8928#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved \u2018complete response\u2019"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8928"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/8929"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}